TrialDiabetes, obesity & metabolism2019

Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial.

Dario Tuccinardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.